Evidence map›Paper›PMID 40947735›Full record

ArticleCurrent drug targets2026

Investigating the Mechanism of Astragalus mongholicus-Mediated Treatment of Silicosis in Mice from the Perspective of Alternative Splicing.

Yu Zhang, Zhiyan Jiang, Yuanyuan Zhai, Yongqiang Xing

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yu ZhangInner Mongolia Key Laboratory of Life Health and Bioinformatics, School of Life Science and Technology, Inner Mongolia University of Science & Technology, Baotou, 014010, China.ORCID 0009-0003-4206-4934
Zhiyan JiangInner Mongolia Key Laboratory of Life Health and Bioinformatics, School of Life Science and Technology, Inner Mongolia University of Science & Technology, Baotou, 014010, China.
Yuanyuan ZhaiInner Mongolia Key Laboratory of Life Health and Bioinformatics, School of Life Science and Technology, Inner Mongolia University of Science & Technology, Baotou, 014010, China.
Yongqiang XingInner Mongolia Key Laboratory of Life Health and Bioinformatics, School of Life Science and Technology, Inner Mongolia University of Science & Technology, Baotou, 014010, China.ORCID 0000-0001-6987-7327

Funding

2025 Inner Mongolia Key Laboratory of Life Health and Bioinformatics Project 2025KYPT0135Basic scientific research funding for universities directly under Inner Mongolia Autonomous Region 2023RCTD023, 2023XKJX014National Natural Science Foundation of China 62371265, 62161039Natural Science Foundation of Inner Mongolia 2024JQ10, 2024MS03054
6 · The paper itself

Abstract

introductionAstragalus mongholicus is distributed in Inner Mongolia, China, and has a certain therapeutic effect on silicosis. However, the regulatory mechanisms of Astragalus mongholicus mediated by alternative splicing (AS) in silicosis pathology and treatment remain unclear.

methodsThe pathological examination was performed on the lung tissue from a constructed mouse model of silicosis. Then, rMATS-based AS detection, target prediction, PPI analysis, and molecular docking were conducted to investigate the mechanism of Astragalus mongholicus-mediated treatment of silicosis in mice from the perspective of AS.

resultsA total of 404 differentially alternatively spliced genes (DASGs) were identified between the Astragalus mongholicus treatment and the silicosis model group. Moreover, 194 potential targets were predicted from 33 active components of Astragalus mongholicus, of which the targets, Rps6ka2 and Clk4, underwent differential AS. Network pharmacology analysis indicated that the Isomucronulatol, 7-o-methylisomucronulatol, and Medicarpin in Astragalus mongholicus might participate in the treatment of silicosis through differential splicing of Rps6ka2 or Clk4. Molecular docking confirmed a strong binding affinity between the protein Rps6ka2 and Medicarpin. DISCUSSION: This study suggests that Isomucronulatol, 7-o-methylisomucronulatol, and Medicarpin, being active components in Astragalus mongholicus, may intervene

conclusionA large number of DASEs exist in the development and treatment of silicosis. Astragalus mongholicus may alleviate silicosis through AS-regulated mechanisms involving Rps6ka2 and Clk4. This finding provides novel strategies and potential molecular targets for silicosis treatment.

Indexed as

Alternative SplicingAstragalus PlantDrugs, Chinese HerbalSilicosisAnimalsDisease Models, AnimalLungMaleMiceMolecular Docking SimulationProtein Serine-Threonine KinasesDrugs, Chinese HerbalProtein Serine-Threonine Kinasesalternative splicingAstragalus mongholicusmolecular docking.network pharmacologyRNA-seqSilicosis

Identifiers

PMID40947735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.